Benzinga | Mar 11, 2021 11:23AM EST

Credit Suisse Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $18

Credit Suisse maintains Flexion Therapeutics (NASDAQ:FLXN) with a Outperform and lowers the price target from $19 to $18.